A Game Changing Drug for Pancreatic Cancer Just Got FDA Approval The US Food and Drug Administration's (FDA) approval of daraxonrasib marks a significant shift in the treatment landscape for pancreatic cancer.
This breakthrough is being hailed as a game changer, but its broader implications and potential impact on patients, researchers, and the future of cancer treatment warrant careful consideration.
The Elusive RAS Target For decades, scientists have sought to target the RAS protein family, which drives up to 90% of pancreatic cancers.